fluvoxamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1230 54739-18-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluvoxamine
  • fluvoxamine maleate
  • depromel
A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS. Because of its high affinity at the sigma-1 receptor, the drug was evaluated whether could prevent clinical deterioration in patients with COVID-19. At the moment, there are insufficient data to recommend either for or against use of fluvoxamine for the treatment of COVID-19.
  • Molecular weight: 318.34
  • Formula: C15H21F3N2O2
  • CLOGP: 2.77
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 56.84
  • ALOGS: -4.64
  • ROTB: 10
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 14.87 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 13.46 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 53 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 23.50 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 31.95 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 12.50 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK3,MAP2K6,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKDC,TEK,TGFBR1,ZAP70 33
kinase-selectivity-class AXL,EPHB4,PDK4 3
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 1.012 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 1
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 High 1
rat-kpuu-brain Rat brain Kpuu 0.334 % High 1

Approvals:

DateAgencyCompanyOrphan
Dec. 5, 1994 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicide attempt 437.03 18.77 191 8809 75208 90544239
Drug interaction 424.97 18.77 290 8710 276163 90343284
Myoglobin urine present 287.92 18.77 52 8948 710 90618737
Serotonin syndrome 245.53 18.77 104 8896 37783 90581664
Intentional overdose 238.79 18.77 136 8864 93698 90525749
Suicidal ideation 223.44 18.77 120 8880 73735 90545712
Toxic encephalopathy 191.26 18.77 59 8941 8640 90610807
Blood creatine phosphokinase increased 189.66 18.77 84 8916 33939 90585508
Amylase increased 172.69 18.77 52 8948 7020 90612427
Troponin increased 162.95 18.77 58 8942 13223 90606224
Intentional self-injury 143.09 18.77 66 8934 29268 90590179
Blood potassium increased 127.86 18.77 55 8945 20694 90598753
Blood lactate dehydrogenase increased 119.18 18.77 56 8944 25876 90593571
Drug abuse 104.11 18.77 77 8923 82270 90537177
Toxicity to various agents 103.79 18.77 135 8865 287711 90331736
Somnolence 103.11 18.77 115 8885 208969 90410478
Neuroleptic malignant syndrome 70.58 18.77 33 8967 15063 90604384
Alanine aminotransferase increased 68.65 18.77 71 8929 118267 90501180
Sopor 55.35 18.77 33 8967 24611 90594836
Brugada syndrome 54.52 18.77 12 8988 463 90618984
Mydriasis 49.85 18.77 26 8974 14986 90604461
Drug level increased 49.26 18.77 32 8968 27730 90591717
Electrocardiogram QT prolonged 48.49 18.77 47 8953 72409 90547038
Completed suicide 47.49 18.77 65 8935 144993 90474454
Obsessive-compulsive disorder 45.31 18.77 17 8983 4487 90614960
Extrapyramidal disorder 45.08 18.77 25 8975 16278 90603169
Oscillopsia 42.58 18.77 8 8992 137 90619310
Overdose 41.88 18.77 64 8936 157645 90461802
Tremor 39.05 18.77 61 8939 153112 90466335
Adverse drug reaction 37.74 18.77 52 8948 116649 90502798
Galactorrhoea 37.62 18.77 15 8985 4657 90614790
Hypotension 36.77 18.77 92 8908 325305 90294142
Schizophrenia 36.19 18.77 21 8979 14893 90604554
Drug level below therapeutic 34.45 18.77 15 8985 5799 90613648
Mental disorder 33.74 18.77 27 8973 32291 90587156
Loss of consciousness 33.20 18.77 54 8946 140184 90479263
Sluggishness 30.89 18.77 14 8986 5945 90613502
Akathisia 30.54 18.77 17 8983 11142 90608305
Condition aggravated 30.24 18.77 128 8872 595417 90024030
Rhabdomyolysis 30.14 18.77 31 8969 51225 90568222
Antipsychotic drug level increased 29.96 18.77 12 8988 3767 90615680
Restlessness 29.37 18.77 26 8974 35694 90583753
Agitation 28.12 18.77 34 8966 67064 90552383
Drug screen false positive 27.68 18.77 8 8992 935 90618512
Anxiety 27.36 18.77 80 8920 309692 90309755
Psychotic disorder 26.21 18.77 23 8977 31207 90588240
Gestational diabetes 25.94 18.77 15 8985 10567 90608880
Torsade de pointes 25.71 18.77 17 8983 15165 90604282
Lactic acidosis 25.22 18.77 28 8972 50435 90569012
Dyspnoea 23.47 18.77 32 8968 880923 89738524
Alopecia 23.32 18.77 10 8990 495061 90124386
Alice in wonderland syndrome 23.11 18.77 4 8996 42 90619405
Metabolic acidosis 22.98 18.77 28 8972 55648 90563799
Akinesia 22.88 18.77 8 8992 1728 90617719
Long QT syndrome 22.57 18.77 10 8990 4027 90615420
Syncope 22.29 18.77 44 8956 132619 90486828
Swelling 22.20 18.77 7 8993 419051 90200396
Altered state of consciousness 22.11 18.77 21 8979 31511 90587936
Infusion related reaction 22.02 18.77 7 8993 416773 90202674
Contraindicated product administered 21.76 18.77 3 8997 320136 90299311
Blood thyroid stimulating hormone increased 19.88 18.77 12 8988 9143 90610304
Aspiration of gastric residual 19.83 18.77 3 8997 12 90619435
Bundle branch block right 19.71 18.77 10 8990 5443 90614004
Blood osmolarity increased 19.60 18.77 5 8995 365 90619082
Congestive cardiomyopathy 19.57 18.77 11 8989 7343 90612104

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 246.04 22.95 270 7446 266729 42346890
Sedation 228.43 22.95 111 7605 30364 42583255
Loss of libido 189.29 22.95 53 7663 3017 42610602
Apathy 151.24 22.95 57 7659 8349 42605270
Suicidal ideation 138.71 22.95 94 7622 48067 42565552
Schizophrenia 135.28 22.95 56 7660 10494 42603125
Salivary hypersecretion 123.34 22.95 53 7663 10890 42602729
Psychotic disorder 118.98 22.95 71 7645 29137 42584482
Serotonin syndrome 116.26 22.95 67 7649 25778 42587841
Antipsychotic drug level increased 107.58 22.95 38 7678 4628 42608991
Drug level increased 89.64 22.95 57 7659 26143 42587476
Tardive dyskinesia 79.54 22.95 34 7682 6890 42606729
Aggression 77.32 22.95 64 7652 44099 42569520
Orthostatic hypotension 74.70 22.95 54 7662 30516 42583103
Neuroleptic malignant syndrome 71.67 22.95 46 7670 21426 42592193
Persecutory delusion 70.79 22.95 26 7690 3538 42610081
Encephalitis toxic 70.58 22.95 15 7701 262 42613357
Intentional overdose 68.85 22.95 64 7652 51392 42562227
Suicide attempt 64.90 22.95 59 7657 46041 42567578
Overdose 64.47 22.95 87 7629 105177 42508442
Delirium 63.94 22.95 62 7654 52457 42561162
Sopor 61.40 22.95 35 7681 13167 42600452
Social avoidant behaviour 61.16 22.95 23 7693 3341 42610278
Depression 60.66 22.95 87 7629 111276 42502343
Toxicity to various agents 60.49 22.95 130 7586 229006 42384613
Enuresis 54.40 22.95 20 7696 2728 42610891
Obsessive-compulsive disorder 51.74 22.95 25 7691 6718 42606901
Weight increased 49.71 22.95 78 7638 107905 42505714
Dysphemia 49.65 22.95 17 7699 1885 42611734
Obesity 49.39 22.95 33 7683 16426 42597193
Somnolence 46.65 22.95 88 7628 141017 42472602
Treatment noncompliance 44.94 22.95 44 7672 37628 42575991
Catatonia 44.48 22.95 22 7694 6217 42607402
Antipsychotic drug level above therapeutic 43.62 22.95 14 7702 1270 42612349
Labelled drug-food interaction issue 42.34 22.95 8 7708 74 42613545
Irritability 41.54 22.95 37 7679 28091 42585528
Drug level below therapeutic 40.58 22.95 21 7695 6524 42607095
Completed suicide 39.37 22.95 66 7650 96399 42517220
Labelled drug-drug interaction medication error 36.85 22.95 27 7689 15555 42598064
Anxiety 36.77 22.95 72 7644 118488 42495131
Mental impairment 35.29 22.95 24 7692 12293 42601326
Sexual dysfunction 34.31 22.95 19 7697 6756 42606863
Obsessive thoughts 31.81 22.95 10 7706 848 42612771
Olfactory nerve disorder 30.98 22.95 6 7710 64 42613555
Psychiatric decompensation 30.43 22.95 15 7701 4207 42609412
Sideroblastic anaemia 30.40 22.95 8 7708 359 42613260
Cardiac dysfunction 30.37 22.95 14 7702 3385 42610234
Hanging 30.21 22.95 7 7709 184 42613435
Drug level decreased 29.92 22.95 20 7696 9957 42603662
Coma scale abnormal 29.32 22.95 15 7701 4550 42609069
Mental disorder 29.19 22.95 25 7691 18004 42595615
Anaemia 28.08 22.95 8 7708 280270 42333349
Thinking abnormal 28.06 22.95 17 7699 7144 42606475
Respiratory fatigue 27.75 22.95 6 7710 114 42613505
Cyclothymic disorder 27.00 22.95 6 7710 130 42613489
Electrocardiogram QT prolonged 26.85 22.95 38 7678 47907 42565712
Akathisia 26.74 22.95 19 7697 10432 42603187
Intentional self-injury 26.51 22.95 22 7694 15180 42598439
Agitation 26.21 22.95 44 7672 64270 42549349
Heat stroke 25.44 22.95 9 7707 1099 42612520
Neonatal behavioural syndrome 25.30 22.95 6 7710 175 42613444
Death 25.22 22.95 29 7687 471156 42142463
Disorientation 25.21 22.95 32 7684 36357 42577262
Motor developmental delay 25.17 22.95 8 7708 703 42612916
Delusion 25.02 22.95 21 7695 14713 42598906
Impulsive behaviour 24.88 22.95 11 7705 2414 42611205
Sexual relationship change 24.68 22.95 4 7712 13 42613606
Brain injury 24.54 22.95 16 7700 7639 42605980
Tremor 24.33 22.95 54 7662 96875 42516744
Arthralgia 24.31 22.95 4 7712 205234 42408385
Dystonia 23.33 22.95 19 7697 12771 42600848
Extrapyramidal disorder 23.06 22.95 21 7695 16391 42597228

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 562.65 17.85 488 14032 499695 110075084
Suicide attempt 399.46 17.85 217 14303 103177 110471602
Serotonin syndrome 347.88 17.85 165 14355 58988 110515791
Suicidal ideation 291.82 17.85 171 14349 93766 110481013
Intentional overdose 265.98 17.85 183 14337 132318 110442461
Myoglobin urine present 257.53 17.85 51 14469 869 110573910
Blood creatine phosphokinase increased 163.39 17.85 108 14412 72969 110501810
Sedation 160.70 17.85 105 14415 69578 110505201
Intentional self-injury 151.10 17.85 81 14439 37348 110537431
Toxicity to various agents 148.88 17.85 243 14277 480312 110094467
Toxic encephalopathy 136.12 17.85 57 14463 15157 110559622
Amylase increased 122.48 17.85 50 14470 12469 110562310
Troponin increased 121.77 17.85 65 14455 29701 110545078
Salivary hypersecretion 119.11 17.85 54 14466 17367 110557412
Neuroleptic malignant syndrome 116.27 17.85 66 14454 33993 110540786
Somnolence 105.20 17.85 160 14360 297289 110277490
Antipsychotic drug level increased 104.32 17.85 38 14482 6977 110567802
Drug level increased 102.94 17.85 69 14451 47650 110527129
Sopor 101.56 17.85 62 14458 36484 110538295
Loss of libido 99.13 17.85 30 14490 3103 110571676
Blood potassium increased 88.80 17.85 55 14465 33194 110541585
Drug abuse 87.44 17.85 112 14408 177299 110397480
Overdose 85.79 17.85 128 14392 233666 110341113
Apathy 85.37 17.85 42 14478 16197 110558582
Completed suicide 82.30 17.85 128 14392 242253 110332526
Psychotic disorder 80.64 17.85 61 14459 50876 110523903
Obsessive-compulsive disorder 78.00 17.85 31 14489 7210 110567569
Blood lactate dehydrogenase increased 76.69 17.85 56 14464 44278 110530501
Aggression 74.61 17.85 62 14458 59148 110515631
Schizophrenia 71.01 17.85 41 14479 21785 110552994
Encephalitis toxic 68.37 17.85 14 14506 284 110574495
Tremor 67.51 17.85 106 14414 202126 110372653
Extrapyramidal disorder 62.86 17.85 42 14478 28825 110545954
Orthostatic hypotension 62.74 17.85 59 14461 66190 110508589
Catatonia 58.72 17.85 29 14491 11271 110563508
Akathisia 57.95 17.85 33 14487 17080 110557699
Drug level below therapeutic 57.83 17.85 29 14491 11644 110563135
Electrocardiogram QT prolonged 55.56 17.85 70 14450 108890 110465889
Tardive dyskinesia 53.69 17.85 29 14491 13550 110561229
Enuresis 52.87 17.85 20 14500 4076 110570703
Agitation 50.43 17.85 68 14452 112983 110461796
Irritability 48.01 17.85 44 14476 47765 110527014
Anxiety 46.37 17.85 124 14396 344954 110229825
Rhabdomyolysis 45.66 17.85 67 14453 120334 110454445
Treatment noncompliance 45.59 17.85 52 14468 72938 110501841
Condition aggravated 44.13 17.85 202 14318 734634 109840145
Dyspnoea 43.38 17.85 49 14471 1106823 109467956
Antipsychotic drug level above therapeutic 43.02 17.85 15 14505 2425 110572354
Adverse drug reaction 41.86 17.85 60 14460 105499 110469280
Labelled drug-food interaction issue 41.28 17.85 8 14512 121 110574658
Brugada syndrome 40.94 17.85 13 14507 1575 110573204
Obsessive thoughts 39.15 17.85 12 14508 1295 110573484
Galactorrhoea 38.61 17.85 16 14504 4139 110570640
Labelled drug-drug interaction medication error 37.56 17.85 31 14489 29271 110545508
Drug reaction with eosinophilia and systemic symptoms 36.03 17.85 49 14471 82046 110492733
Mental impairment 35.57 17.85 27 14493 22612 110552167
Olfactory nerve disorder 34.80 17.85 6 14514 45 110574734
Pain 34.50 17.85 45 14475 954910 109619869
Mydriasis 33.87 17.85 26 14494 22131 110552648
Alanine aminotransferase increased 33.14 17.85 74 14446 183699 110391080
Parkinsonism 31.67 17.85 25 14495 22162 110552617
Oscillopsia 31.65 17.85 8 14512 424 110574355
Hanging 31.62 17.85 7 14513 208 110574571
Sideroblastic anaemia 31.35 17.85 8 14512 441 110574338
Arthralgia 31.05 17.85 34 14486 779598 109795181
Delirium 30.94 17.85 60 14460 134965 110439814
Febrile neutropenia 30.75 17.85 3 14517 316764 110258015
Psychiatric decompensation 30.56 17.85 15 14505 5750 110569029
Long QT syndrome 30.39 17.85 16 14504 7102 110567677
Distributive shock 30.22 17.85 15 14505 5889 110568890
Delusion 30.17 17.85 25 14495 23730 110551049
Cyclothymic disorder 30.06 17.85 7 14513 262 110574517
Loss of consciousness 29.90 17.85 74 14446 196232 110378547
Mental disorder 28.31 17.85 30 14490 38761 110536018
Drug ineffective 28.30 17.85 314 14206 1520226 109054553
Pneumonia 28.02 17.85 45 14475 876669 109698110
Sexual dysfunction 27.68 17.85 16 14504 8514 110566265
Depressed level of consciousness 27.09 17.85 51 14469 112227 110462552
Restlessness 26.86 17.85 35 14485 56224 110518555
Sexual relationship change 26.47 17.85 4 14516 11 110574768
Peripheral swelling 26.43 17.85 10 14510 404024 110170755
Infusion related reaction 25.66 17.85 9 14511 381153 110193626
Dissociation 25.56 17.85 16 14504 9826 110564953
Drooling 24.80 17.85 14 14506 7125 110567654
Gaze palsy 24.68 17.85 11 14509 3396 110571383
Dystonia 24.45 17.85 23 14497 25782 110548997
Inappropriate antidiuretic hormone secretion 24.39 17.85 26 14494 33825 110540954
Hallucination 24.37 17.85 46 14474 101386 110473393
Respiratory fatigue 24.24 17.85 6 14514 292 110574487
Alopecia 23.90 17.85 9 14511 364744 110210035
Cardiac dysfunction 23.79 17.85 13 14507 6210 110568569
Drug intolerance 23.52 17.85 12 14508 406500 110168279
Hypersensitivity 23.27 17.85 12 14508 403986 110170793
Brain injury 23.24 17.85 17 14503 13459 110561320
Coma scale abnormal 23.24 17.85 15 14505 9711 110565068
Hypotension 22.97 17.85 132 14388 523717 110051062
Pulmonary embolism 22.88 17.85 71 14449 214403 110360376
Activation syndrome 22.79 17.85 6 14514 374 110574405
Stomatitis 22.79 17.85 4 14516 270238 110304541
Mania 22.57 17.85 20 14500 20776 110554003
Drug screen false positive 22.55 17.85 8 14512 1361 110573418
Psychomotor skills impaired 22.27 17.85 13 14507 7045 110567734
Disorientation 22.11 17.85 36 14484 70635 110504144
Bradycardia 21.98 17.85 57 14463 155460 110419319
Impulsive behaviour 21.78 17.85 10 14510 3305 110571474
Orgasmic sensation decreased 21.42 17.85 4 14516 49 110574730
Anorgasmia 21.11 17.85 8 14512 1638 110573141
Acanthosis nigricans 21.01 17.85 5 14515 206 110574573
Diarrhoea 20.99 17.85 78 14442 1139427 109435352
Alice in wonderland syndrome 20.93 17.85 4 14516 56 110574723
Potentiating drug interaction 20.79 17.85 15 14505 11628 110563151
Hyperprolactinaemia 20.45 17.85 12 14508 6563 110568216
Respiratory depression 20.31 17.85 23 14497 31978 110542801
Semen volume decreased 20.31 17.85 4 14516 66 110574713
Altered state of consciousness 20.31 17.85 31 14489 57595 110517184
Rheumatoid arthritis 20.29 17.85 7 14513 299606 110275173
Premature ejaculation 20.20 17.85 4 14516 68 110574711
Muscle rigidity 20.10 17.85 20 14500 24011 110550768
Heat stroke 19.85 17.85 8 14512 1927 110572852
Abnormal behaviour 19.76 17.85 25 14495 39014 110535765
Myoclonus 19.74 17.85 23 14497 32975 110541804
Swelling 19.37 17.85 11 14509 351030 110223749
Glossodynia 19.35 17.85 3 14517 222001 110352778
Self-injurious ideation 19.21 17.85 10 14510 4336 110570443
Schizoaffective disorder 19.18 17.85 9 14511 3127 110571652
Infection 19.08 17.85 12 14508 362188 110212591
Hyperhidrosis 19.05 17.85 61 14459 187237 110387542
Wheezing 19.03 17.85 5 14515 255225 110319554
Torticollis 18.95 17.85 9 14511 3212 110571567
Blood prolactin increased 18.59 17.85 10 14510 4632 110570147
Aspiration of gastric residual 18.44 17.85 3 14517 15 110574764
Tic 18.25 17.85 9 14511 3484 110571295

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AB08 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Selective serotonin reuptake inhibitors
FDA MoA N0000000109 Serotonin Uptake Inhibitors
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:35469 antidepressant
CHEBI has role CHEBI:35474 anxiolytic drug
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50949 serotonin uptake inhibitor
CHEBI has role CHEBI:149553 anticoronaviral agent
MeSH PA D000928 Antidepressive Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D018687 Antidepressive Agents, Second-Generation
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D065607 Cytochrome P-450 Enzyme Inhibitors
MeSH PA D065609 Cytochrome P-450 CYP1A2 Inhibitors
MeSH PA D065689 Cytochrome P-450 CYP2C19 Inhibitors
FDA EPC N0000175696 Serotonin Reuptake Inhibitor

Related Drugs by ATC class:

N06AB Selective serotonin reuptake inhibitors 7 drugs
citalopramescitaloprametoperidonefluoxetineparoxetinesertralinezimeldine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Social phobia indication 25501002 DOID:11257
Obsessive-compulsive disorder indication 191736004 DOID:10933
Depressive disorder off-label use 35489007
Posttraumatic stress disorder off-label use 47505003 DOID:2055
Bipolar affective disorder, current episode depression off-label use 191627008 DOID:3312
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Upper gastrointestinal hemorrhage contraindication 37372002
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Epilepsy contraindication 84757009 DOID:1826
Hyponatremia contraindication 89627008
Mania contraindication 231494001
Hypomania contraindication 231496004
Disease of liver contraindication 235856003 DOID:409
Serotonin syndrome contraindication 371089000
Breastfeeding (mother) contraindication 413712001
Poor metabolizer due to cytochrome p450 CYP2D6 variant contraindication 423629005
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.36 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.51 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.95 PDSP
Sodium-dependent dopamine transporter Transporter Ki 8.84 CHEMBL
Cytochrome P450 1A2 Enzyme Ki 5.07 WOMBAT-PK
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sodium-dependent serotonin transporter Transporter INHIBITOR Ki 8.19 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.44 CHEMBL
Sigma intracellular receptor 2 Membrane receptor Ki 5.07 CHEMBL

External reference:

IDSource
4023976 VUID
N0000021981 NUI
D00824 KEGG_DRUG
61718-82-9 SECONDARY_CAS_RN
4020892 VANDF
4023976 VANDF
C0085228 UMLSCUI
CHEBI:5138 CHEBI
FVX PDB_CHEM_ID
CHEMBL814 ChEMBL_ID
DB00176 DRUGBANK_ID
CHEMBL1409 ChEMBL_ID
D016666 MESH_DESCRIPTOR_UI
5324346 PUBCHEM_CID
7189 IUPHAR_LIGAND_ID
3879 INN_ID
O4L1XPO44W UNII
203143 RXNORM
40916 MMSL
4758 MMSL
d03804 MMSL
003633 NDDF
003634 NDDF
116522003 SNOMEDCT_US
372905008 SNOMEDCT_US
96213009 SNOMEDCT_US
O4L1XPO44W INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2848 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0228-2849 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-175 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 29 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 10370-176 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 29 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 16590-270 TABLET 25 mg ORAL NDA 11 sections
Fluvoxamine Maleate Human Prescription Drug Label 1 27241-274 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 32 sections
Fluvoxamine Maleate Human Prescription Drug Label 1 27241-275 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 31722-064 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 31722-065 CAPSULE, EXTENDED RELEASE 150 mg ORAL ANDA 30 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 33261-683 TABLET, COATED 50 mg ORAL NDA AUTHORIZED GENERIC 31 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-5988 TABLET, COATED 100 mg ORAL NDA authorized generic 31 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 50090-7728 TABLET 100 mg ORAL ANDA 33 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0164 TABLET 25 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0165 TABLET 50 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 60505-0166 TABLET 100 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 62135-931 TABLET, FILM COATED 25 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 62135-932 TABLET, FILM COATED 50 mg ORAL ANDA 20 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 62135-933 TABLET, FILM COATED 100 mg ORAL ANDA 20 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-158 TABLET, COATED 25 mg ORAL NDA authorized generic 30 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-159 TABLET, COATED 50 mg ORAL NDA authorized generic 30 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 62559-160 TABLET, COATED 100 mg ORAL NDA authorized generic 30 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68071-2337 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68084-837 TABLET 50 mg ORAL ANDA 32 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68151-0637 TABLET, COATED 50 mg ORAL NDA authorized generic 31 sections
Fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-4011 TABLET 100 mg ORAL ANDA 34 sections
fluvoxamine maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-7219 TABLET, COATED 100 mg ORAL NDA authorized generic 30 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 68788-8175 TABLET 100 mg ORAL ANDA 32 sections
Fluvoxamine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 69452-182 CAPSULE, EXTENDED RELEASE 100 mg ORAL ANDA 22 sections